In gastric cancer, the activation of PERK significantly increases the G-1-induced apoptosis, while the silencing of PERK leads to increased cell apoptosis, suggesting that the PERK pathway may enhance the therapeutic effect of anti-cancer drugs 23. This evidence concerns the gene EIF2AK3 and gastric cancer.